Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.
Bueno C, Barrera S, Bataller A, Ortiz-Maldonado V, Elliot N, O'Byrne S, Wang G, Rovira M, Gutierrez-Agüera F, Trincado JL, González-González M, Morgades M, Sorigué M, Bárcena P, Zanetti SR, Torrebadell M, Vega-Garcia N, Rives S, Mallo M, Sole F, Mead AJ, Roberts I, Thongjuea S, Psaila B, Juan M, Delgado J, Urbano-Ispizúa A, Ribera JM, Orfao A, Roy A, Menendez P. Bueno C, et al. Among authors: bataller a. Blood. 2022 Jul 7;140(1):38-44. doi: 10.1182/blood.2021014840. Blood. 2022. PMID: 35421218 Free PMC article.
Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations.
Urrutia S, Li Z, Almanza E, Bataller A, Kanagal-Shamanna R, Senapati J, Sasaki K, Chien K, Montalban-Bravo G, DiNardo C, Borthakur G, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Urrutia S, et al. Among authors: bataller a. Leukemia. 2023 Jun;37(6):1397-1400. doi: 10.1038/s41375-023-01899-9. Epub 2023 Apr 25. Leukemia. 2023. PMID: 37185307 No abstract available.
Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours.
Almanza-Huante E, Bataller A, Urrutia S, Gener-Ricos G, Briski RE, Kanagal-Shamanna R, Lu KH, Westin SN, Yap TA, Takahashi K, Ravandi F, Alvarado Y, Kadia T, Sasaki K, Kantarjian HM, Garcia-Manero G. Almanza-Huante E, et al. Among authors: bataller a. Br J Haematol. 2023 May;201(3):e25-e29. doi: 10.1111/bjh.18766. Epub 2023 Mar 23. Br J Haematol. 2023. PMID: 36951293 No abstract available.
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.
Baroni ML, Sanchez Martinez D, Gutierrez Aguera F, Roca Ho H, Castella M, Zanetti SR, Velasco Hernandez T, Diaz de la Guardia R, Castaño J, Anguita E, Vives S, Nomdedeu J, Lapillone H, Bras AE, van der Velden VHJ, Junca J, Marin P, Bataller A, Esteve J, Vick B, Jeremias I, Lopez A, Sorigue M, Bueno C, Menendez P. Baroni ML, et al. Among authors: bataller a. J Immunother Cancer. 2020 Jun;8(1):e000845. doi: 10.1136/jitc-2020-000845. J Immunother Cancer. 2020. PMID: 32527933 Free PMC article.
The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients.
Mozas P, Sorigué M, Rivas-Delgado A, Rivero A, Correa JG, Castillo C, Nadeu F, Bataller A, Giné E, Baumann T, Delgado J, Villamor N, Campo E, Magnano L, Sancho JM, López-Guillermo A. Mozas P, et al. Among authors: bataller a. Eur J Haematol. 2021 Mar;106(3):428-432. doi: 10.1111/ejh.13556. Epub 2020 Dec 14. Eur J Haematol. 2021. PMID: 33247499 No abstract available.
Engraftment characterization of risk-stratified AML in NSGS mice.
Díaz de la Guardia R, Velasco-Hernandez T, Gutiérrez-Agüera F, Roca-Ho H, Molina O, Nombela-Arrieta C, Bataller A, Fuster JL, Anguita E, Vives S, Zamora L, Nomdedeu J, Gómez-Casares MT, Ramírez-Orellana M, Lapillonne H, Ramos-Mejia V, Rodríguez-Manzaneque JC, Bueno C, Lopez-Millan B, Menéndez P. Díaz de la Guardia R, et al. Among authors: bataller a. Blood Adv. 2021 Dec 14;5(23):4842-4854. doi: 10.1182/bloodadvances.2020003958. Blood Adv. 2021. PMID: 34470043 Free PMC article.
A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL.
Zanetti SR, Velasco-Hernandez T, Gutierrez-Agüera F, Díaz VM, Romecín PA, Roca-Ho H, Sánchez-Martínez D, Tirado N, Baroni ML, Petazzi P, Torres-Ruiz R, Molina O, Bataller A, Fuster JL, Ballerini P, Juan M, Jeremias I, Bueno C, Menéndez P. Zanetti SR, et al. Among authors: bataller a. Mol Ther. 2022 Feb 2;30(2):550-563. doi: 10.1016/j.ymthe.2021.08.033. Epub 2021 Sep 1. Mol Ther. 2022. PMID: 34478871 Free PMC article.
KMT2A-CBL rearrangements in acute leukemias: clinical characteristics and genetic breakpoints.
Bataller A, Guijarro F, Caye-Eude A, Strullu M, Sterin A, Molina O, Chevallier P, Zaliova M, Zuna J, Mozas P, Magnano L, Grardel N, Cornillet-Lefebvre P, Fu JF, Shih LY, Boneva T, Nacheva E, Beà S, López-Guerra M, Bueno C, Menéndez P, Esteve J, Larghero P, Meyer C, Marschalek R. Bataller A, et al. Blood Adv. 2021 Dec 28;5(24):5617-5620. doi: 10.1182/bloodadvances.2021005736. Blood Adv. 2021. PMID: 34638131 Free PMC article. No abstract available.
72 results